Next generation antidepressants : moving beyond monoamines to discover novel treatment strategies for mood disorders
Author(s)
Bibliographic Information
Next generation antidepressants : moving beyond monoamines to discover novel treatment strategies for mood disorders
(Cambridge medicine)
Cambridge University Press, 2010
- : hardback
Available at 1 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references and index
Contents of Works
- Current depression landscape : a state of the field today / Laurence Mignon and Stephen M. Stahl
- Novel therapeutic targets for treating affective disorders / Eliyahu Dremencov and Thomas I. F. H. Cremers
- Developing novel animal models of depression / Lotte de Groote, Malgorzata Filip, and Andrew C. McCreary
- Translational research in mood disorders : using imaging technologies in biomarker research / Jul Lea Shamy ... [et al.]
- Defining depression endophenotypes / Lisa H. Berghorst and Diego A. Pizzagalli
- Genetic and genomic studies of major depressive disorder / Roy H. Perlis
- Medicinal chemistry challenges in the design of next generation antidepressants / David P. Rotella
- Application of pharmacogenomics and personalized medicine for the care of depression / Keh-Ming Lin, Chun-Yu Chen, and Yu-Jui Yvonne Wan
Description and Table of Contents
Description
The World Health Organization defines depression as a primary contributor to the global burden of disease and predicts it will become the second leading cause of death by 2020. The need to develop effective therapies has never been so pressing. Current antidepressant drugs have several limitations. This 2010 book looks at the future of mood-disorder research, covering the identification of new therapeutic targets, establishing new preclinical models, new medicinal chemistry opportunities, and fostering greater understanding of genetic influences. These strategies are likely to help build a better picture of the disease process, and lead to new opportunities for patient stratification and treatment. The ultimate goal for this strand of research is to develop more personalized and effective treatments for this chronic and debilitating condition. This is essential reading for all those involved in psychopharmacologic drug development, and mental health clinicians seeking a preview of discoveries soon to influence their practice.
Table of Contents
- Preface Chad E. Beyer
- 1. Current depression landscape: a state of the field today Laurence Mignon and Stephen M. Stahl
- 2. Novel therapeutic targets for treating affective disorders Eliyahu Dremencov and Thomas Cremers
- 3. Developing novel animal models of depression Lotte de Groote, Malgorzata Filip and Andrew C. McCreary
- 4. Translational research in mood disorders: using imaging technologies in biomarker research Jul Lea Shamy, Adam M. Brickman, Chris D. Griesemer, Anna Parachikova and Mark Day
- 5. Defining depression endophenotypes Lisa H. Berghorst and Diego A. Pizzagalli
- 6. Genetic and genomic studies of major depressive disorder Roy H. Perlis
- 7. Medicinal chemistry challenges in the design of next generation antidepressants David P. Rotella
- 8. Application of pharmacogenomics and personalized medicine for the care of depression Keh-Ming Lin, Chun-Yu Chen and Yu-Jui Yvonne Wan
- Index.
by "Nielsen BookData"